Drugs & Aging

, Volume 6, Issue 5, pp 345–350 | Cite as

Screening for Prostate Cancer

Implications for Drug Therapy
  • Rowan H. Harwood
Leading Article


Flutamide Leuprorelin Prostate Cancer Screening Nilutamide Androgen Receptor Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gerber G, Chodak GW. Routine screening for cancer of the prostate. J Natl Cancer Inst 1991; 83: 329–35PubMedCrossRefGoogle Scholar
  2. 2.
    Garnick MB. Prostate cancer: screening diagnosis and management. Ann Intern Med 1993; 118: 804–18PubMedGoogle Scholar
  3. 3.
    Catalona WJ. Screening for prostate cancer. Lancet 1994; 343: 1437PubMedGoogle Scholar
  4. 4.
    Adolfsson J, Steineck G, Whitmore WF. Recent results of management of palpable clinical localised prostate cancer. Cancer 1993; 72: 310–22PubMedCrossRefGoogle Scholar
  5. 5.
    Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retick AB, et al., editors. Campbell’s urology. 6th ed. Philadelphia: WB Saunders 1991; 1159–215Google Scholar
  6. 6.
    Smith PH. The case for no initial treatment of localised prostate cancer. Urol Clin North Am 1990; 17: 827–34PubMedGoogle Scholar
  7. 7.
    Sogani PC, Fair WR. Treatment of advanced prostate cancer. Urol Clin North Am 1987; 14: 353–71PubMedGoogle Scholar
  8. 8.
    Wilson JMG, Jungner G. Principals and practice of screening for disease. Geneva: World Health Organisation, 1968Google Scholar
  9. 9.
    Harwood RH. Should we screen for prostate cancer. Age Ageing 1994; 23: 164–8PubMedCrossRefGoogle Scholar
  10. 10.
    Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958–60PubMedCrossRefGoogle Scholar
  11. 11.
    Mettlin C. The status of prostate cancer early detection. Cancer 1993; 72: 1050–5PubMedCrossRefGoogle Scholar
  12. 12.
    Lu-Yao GL, Greenberg RE. Changes in prostate cancer incidence and treatment in USA. Lancet 1994; 343: 251–4PubMedCrossRefGoogle Scholar
  13. 13.
    Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localised prostate cancer. N Engl J Med 1994; 330: 242–8PubMedCrossRefGoogle Scholar
  14. 14.
    Whitmore WF. Overview: historical and contemporary. Natl Cancer Inst Monogr 1988; 7: 7–11Google Scholar
  15. 15.
    Meyers FJ. Tumor biology in explanation of the failure of screening and in determining of future strategies. JAMA 1986; 80: 911–6Google Scholar
  16. 16.
    Gittes RF. Carcinoma of the prostate. N Engl J Med 1991; 324: 236–45PubMedCrossRefGoogle Scholar
  17. 17.
    Kramer BS, Brown ML, Prorok PC, et al. Prostate cancer: what we know and what we need to know. Ann Intern Med 1993; 914–23Google Scholar
  18. 18.
    Thompson IM, Rounder JB, Teague JL. Impact of routine screening for carcinoma of the prostate on stage distribution. J Urol 1987; 137: 424–6PubMedGoogle Scholar
  19. 19.
    Santen RJ. Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992: 75: 685–9PubMedCrossRefGoogle Scholar
  20. 20.
    Ruizeveld de Winter JA, Jannsen PJA, Sleddens HMEB, et al. Androgen receptor status in localised and locally progressive hormone refractory human prostate cancer. Am J Pathol 1994; 144: 735–46PubMedGoogle Scholar
  21. 21.
    Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967; 124; 1011–7Google Scholar
  22. 22.
    Veterans Administration Co-operative Urological Research Group. Carcinoma of the prostate: treatment comparisons. J Urol 1967; 98: 516–22Google Scholar
  23. 23.
    Byar DP, VACURG. Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of conservative treatment. J Urol 1972; 108: 908–13PubMedGoogle Scholar
  24. 24.
    Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the VACURG studies. NCI Monographs 1988; 7: 165–70PubMedGoogle Scholar
  25. 25.
    Byar DP. The VACURG studies of cancer of the prostate. Cancer 1973; 1126–30Google Scholar
  26. 26.
    Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostate carcinoma: early versus late endocrine therapy. Urol Clin North Am 18: 15–24Google Scholar
  27. 27.
    Fellows GJ, Clark PB, Beynon LL, et al. Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy or combined treatment: an MRC study. Br J Urol 1992; 70; 304–9PubMedGoogle Scholar
  28. 28.
    Fossa SD, Aaronson NK, Newling D, et al. Quality of life and treatment of hormone resistant prostatic cancer. Eur J Cancer 1990; 26; 1133–6PubMedCrossRefGoogle Scholar
  29. 29.
    Kirk D. Trials and tribulations in prostate cancer. Br J Urol 1987; 59: 375–9PubMedCrossRefGoogle Scholar
  30. 30.
    Research ethics. MRC multicentre trial of orchiectomy in carcinoma of the prostate. Bull Inst Med Ethics 1986; March: 1–7Google Scholar
  31. 31.
    De Kernion JB, Neuwirth H, Stein A, et al. Prognosis of patients with stage D1 prostate cancer following radical prostatectomy with and without early endocrine therapy. J Urol 1990; 144: 700–3Google Scholar
  32. 32.
    Kramolowsky EV. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988; 139: 1242–4PubMedGoogle Scholar
  33. 33.
    Zincke H. Extended experience with surgical treatment of stage D1 adenocarcinoma of the prostate: significant influences of immediate adjuvant hormonal treatment (orchiectomy) on outcome. Urology 1989; 33 Suppl. 5: 27–36PubMedCrossRefGoogle Scholar
  34. 34.
    Belt E, Schroder FH. Total perineal prostatectomy for carcinoma of the prostate. J Urol 1972; 107: 91–6PubMedGoogle Scholar
  35. 35.
    Grossman HB. Hormonal therapy of prostatic carcinoma: is there a rationale for delayed treatment? Urology 1986; 27: 199–204PubMedCrossRefGoogle Scholar
  36. 36.
    Harris MG, Coleman SG, Faulds D, Chrisp P. Nilutamide: a review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Prostate Cancer. Drugs Aging 1993; 3(1): 9–25PubMedCrossRefGoogle Scholar
  37. 37.
    Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic cancer. N Engl J Med 1989; 321: 419–24PubMedCrossRefGoogle Scholar
  38. 38.
    Dearnaly DP. Cancer of the prostate. BMJ 1994; 308: 780–4CrossRefGoogle Scholar
  39. 39.
    Waxman J, Saini A. The current status of scientific research and hormonal treatments for carcinoma of the prostate. Br J Cancer 1991; 64: 419–21PubMedCrossRefGoogle Scholar
  40. 40.
    Bilgrami S, Greenberg B. Cost-effectiveness of prostate cancer screening and treatment. Ann Intern Med 1993; 119: 1054–5PubMedGoogle Scholar
  41. 41.
    Schroder FH. Adjuvant endocrine treatment in early prostatic cancer. Acta Oncologica 1991; 30: 255–8PubMedCrossRefGoogle Scholar
  42. 42.
    Paulson DF, Lin GH, Hinshaw W, et al. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982; 128: 502–5PubMedGoogle Scholar
  43. 43.
    Fleming C, Wasson JH, Albertsen PC, et al. A decision analysis of alternate treatment strategies for clinically localised prostate cancer. JAMA 1993; 269: 2650–8PubMedCrossRefGoogle Scholar
  44. 44.
    Sox HC, Blatt M, Marton K. Medical decision making. London: Butterworths, 1988Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Rowan H. Harwood
    • 1
  1. 1.Department of Public HealthRoyal Free HospitalLondonEngland

Personalised recommendations